Now ideas for wellness

About Meiji

At a Glance

At a Glance

Get to know Meiji at a glance – from our core business to our most important numbers.

Pharmaceuticals

R&D

Medical needs are always diversifying – here's how Meiji is responding.

Pipeline

As of August 9, 2022

  • Clinical Trial
  • Japan
  • Outside of Japan

In-house drug discovery

Infectious Diseases

FYE March 2023 FYE March 2024 FYE March 2025
OP0595 Nacubactam: [β-lactamase inhibitor] Phase I
with
β-Lactams
Phase III

More about our work in the field of infectious diseases:

LEARN MORE

Others

FYE March 2023 FYE March 2024 FYE March 2025
HBI-8000 Tucidinostat: [Relapsed or refractory peripheral T-cell lymphoma (PTCL)] *1 Approved blank
ME3208 Belumosudil: [Chronic Graft Versus Host Disease] *2 Phase III
DMB-3115 Ustekinumab biosimilar: [Plaque psoriasis, Psoriatic arthritis, Crohn's disease, Ulcerative colitis] *3 Phase III Apply Approve
Phase I Apply Approve
ME3183: [Psoriasis/Selective PDE4 inhibitor] Phase IIa
HBI-8000 Tucidinostat: [Relapsed or refractory B-cell non-Hodgkin's lymphoma] *4 Phase Ib/II
DMB-3111 Trastuzumab biosimilar: [Breast cancer, Gastric cancer] *5 (P I finished)

*1 Development: HUYABIO International, LLC (USA)

*2 Development: Romeck Pharma, LLC

*3 Co-development: Dong-A Socio Holdings Co., Ltd. (South Korea)
Out-license: Intas Pharmaceuticals Ltd. (India)

*4 In-license: HUYABIO International, LLC (USA)

*5 Co-development: Dong-A Socio Holdings Co., Ltd. (South Korea)

Vaccines

FYE March 2023 FYE March 2024 FYE March 2025
KD-370: [Pentavalent vaccine against diphtheria, tetanus, pertussis, polio, and haemophilus influenza type b] Phase III Applied Approve
Phase II blank
KD-414: [Inactivated vaccine against COVID-19] Phase I / II
Phase II / III
Phase II/III
(Pediatric
Clinical Trials)
Phase III
(Adults under 40) *6
KD-404: [Egg-derived inactivated whole virus influenza vaccine] *7 Phase
I / II
KD-382: [Quadrivalent vaccine against dengue fever] Phase I

*6 Multi-Regional Clinical Trials

*7 Cooperation: Hokkaido University

More about our work in the field of vaccines:

LEARN MORE

Blood Plasma Products

FYE March 2023 FYE March 2024 FYE March 2025
KD2-305: [Suppression of bleeding tendency in patients with blood coagulation factor VIII or factor IX deficiency who have coagulation factor inhibitors] Applied Approve
Extension study blank

More about our work in the field of blood plasma:

LEARN MORE

Veterinary Drugs

FYE March 2023 FYE March 2024 FYE March 2025
ME4137: [Injectable antibacterial drugs for cattle use] Applied Approve
ME4137: [Injectable antibacterial drugs for swine use] Applied Approve
ME4406: [Feed additive] Apply
ME4305: [Antibacterial drugs for cattle use] Apply
KD-412: [Vaccine for cattle use] Applied Approve
MD-1001-1: [Injectable antibacterial drugs for cattle use] Apply

More about our work in the field of veterinary drugs:

LEARN MORE